DJIA 16,791.46 -251.44 -1.48%
NASDAQ 4,414.55 -78.84 -1.75%
S&P 500 1,942.14 -30.15 -1.53%
market minute promo

Gilead Sciences (NASDAQ: GILD)

105.38 -1.07 (-1.01%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GILD $105.30 -1.08%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $106.99
Previous Close $106.45
Daily Range $105.26 - $107.59
52-Week Range $58.81 - $110.64
Market Cap $159.3B
P/E Ratio 23.98
Dividend (Yield) $0.00 (0.0%)
Volume 7,546,550
Average Daily Volume 14,848,414
Current FY EPS $7.26





Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website:

News & Commentary

Did Achillion Pharmaceuticals, Inc. Get Left Out in the M&A Cold?

Speculation that Achillion could be a takeover target was dampened following Johnson & Johnson's acquisition of Alios this week.

Why Gilead Sciences (GILD) Stock Is Declining Today

Round 2 of Gilead Sciences, Inc.'s Offensive Begins

A key European advisory panel recommends Gilead's Harvoni for EU approval.

#PreMarket Primer: Wednesday, October 1: First Case Of Ebola In The US Confirmed

#PreMarket Primer: Wednesday, October 1: First Case Of Ebola In The US Confirmed

CorMedix Files IND Application for Neutrolin in the US - Analyst Blog

AMAG Up on Roughly $1B deal with Lumara to Widen Portfolio - Analyst Blog

4 Predictions For The Fourth Quarter

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax

Gilead Sciences, Inc. Stock's Stunning New Opportunity

The biotech giant has spent over $1.2 billion to buy blood cancer drugs. And with Zydelig's recent approval, it looks like it's finally struck gold.

See More GILD News...

GILD's Top Competitors

GILD $105.38 (-1.01%)
Current stock: GILD
AMGN $138.50 (-1.40%)
Current stock: AMGN
CELG $93.02 (-1.86%)
Current stock: CELG
$0.00 (0.00%)
Current stock: